Compare Goldman Sachs Group Inc (GS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs BIO-TECHNE Corp — how do they compare? Goldman Sachs Group Inc trades at $887 (market cap $258.33B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Goldman Sachs Group Inc is far larger — about 22.7× BIO-TECHNE Corp's market cap, and Goldman Sachs Group Inc pays the higher dividend (2.25%). Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and BIO-TECHNE Corp for 63 Days on average.
| GS | TECH | |
|---|---|---|
Market Cap | $258.33B | $11.37B |
Volume | 2,388,334 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $1.15K | $72.61 |
52-Week Low | $744.60 | $43.31 |
Typical Hold Time | 101 Days | 63 Days |
Enterprise Value | $816.34B | $11.40B |
Dividend Yield | 2.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 1.63% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $20.98 versus $14.47 expected. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 31.68%. Recent news highlights the company's focus on expanding to a $70B revenue base and AI initiatives.
The outlook remains positive with analyst consensus target of $1,130 representing 28% upside potential. Key risks include volatile cash flows with negative operating cash of -$45.15B in 2025 and potential FICC business softness. The current valuation at P/E of 13.7 appears attractive relative to earnings growth trajectory.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
